SDX-7320 elicits improvements in tumor-related and metabolic biomarkers: Results of a phase 1 dose-escalation study in patients with advanced refractory or late-stage solid tumors

This article has no abstract
Epistemonikos ID: 9e296689457404d2a0d10f5b40a868558c312864
First added on: Feb 12, 2025